{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:37:25Z","timestamp":1791311845328,"version":"4.3.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jaci.2024.07.014","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T23:10:09Z","timestamp":1722035409000},"page":"1241-1248.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Preclinical efficacy of peanut-specific IgG4 antibody therapeutic IGNX001"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4907-1865","authenticated-orcid":false,"given":"Derek","family":"Croote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce J.W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Creeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venu","family":"Aruva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Landers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Jama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra F.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica J.","family":"O\u2019Konek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Ferrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Roger","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry B.","family":"Lowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.07.014_bib1","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jaci.2010.03.029","article-title":"US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up","volume":"125","author":"Sicherer","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/all.14666","article-title":"The global burden of illness of peanut allergy: a comprehensive literature review","volume":"76","author":"Lieberman","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.07.014_bib3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaci.2012.10.048","article-title":"Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens","volume":"131","author":"Vickery","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib4","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.aau2599","article-title":"High-affinity allergen-specific human antibodies cloned from single IgE B cell transcriptomes","volume":"362","author":"Croote","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jaci.2024.07.014_bib5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jaci.2023.08.035","article-title":"Widespread monoclonal IgE antibody convergence to an immunodominant, proanaphylactic Ara h 2 epitope in peanut allergy","volume":"153","author":"Croote","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib6","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1074\/jbc.M114.600973","article-title":"The S228P mutation prevents in\u00a0vivo and in\u00a0vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation","volume":"290","author":"Silva","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2024.07.014_bib7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0145-2126(02)00343-0","article-title":"Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma\/leukemia: activation following aggregation of FcepsilonRI or FcgammaRI","volume":"27","author":"Kirshenbaum","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2024.07.014_bib8","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jaci.2021.08.006","article-title":"A novel functional mast cell assay for the detection of allergies","volume":"149","author":"Zb\u00e4ren","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nbt.1553","article-title":"Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in\u00a0vivo","volume":"27","author":"Labrijn","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaci.2024.07.014_bib10","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaci.2020.03.026","article-title":"Ara h 2 is the dominant peanut allergen despite similarities with Ara h 6","volume":"146","author":"Hemmings","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2222.2004.1923.x","article-title":"Relevance of Ara h1, Ara h2 and Ara h3 in peanut-allergic patients, as determined by immunoglobulin E Western blotting, basophil-histamine release and intracutaneous testing: Ara h2 is the most important peanut allergen","volume":"34","author":"Koppelman","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.07.014_bib12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jaci.2020.11.034","article-title":"Ara h 2-specific IgE is superior to whole peanut extract-based serology or skin prick test for diagnosis of peanut allergy in infancy","volume":"147","author":"Keet","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cei\/uxae005","article-title":"Defining the cross-reactivity between peanut allergens Ara h 2 and Ara h 6 using monoclonal antibodies","volume":"216","author":"Marini-Rapoport","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jaci.2015.01.012","article-title":"IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens","volume":"135","author":"Santos","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaci.2018.03.011","article-title":"A novel human mast cell activation test for peanut allergy","volume":"142","author":"Santos","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jaci.2023.03.027","article-title":"IgG:Fc\u03b3RIIb signals block effector programs of IgE:Fc\u03b5RI-activated mast cells but spare survival pathways","volume":"152","author":"Kanagaratham","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.603050","article-title":"IgE and IgG antibodies as regulators of mast cell and basophil functions in food allergy","volume":"11","author":"Kanagaratham","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib18","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaci.2011.11.029","article-title":"Reduction of total IgE by targeted coengagement of IgE B-cell receptor and Fc\u03b3RIIb with Fc-engineered antibody","volume":"129","author":"Chu","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib19","doi-asserted-by":"crossref","first-page":"9036","DOI":"10.1073\/pnas.88.20.9036","article-title":"Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1\/IgG2 hybrid and point-mutated antibodies","volume":"88","author":"Chappel","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2024.07.014_bib20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi0673","article-title":"CD23+IgG1+ memory B cells are poised to switch to pathogenic IgE production in food allergy","volume":"16","author":"Ota","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2024.07.014_bib22","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/s41467-018-03636-8","article-title":"Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement","volume":"9","author":"Orengo","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2024.07.014_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaci.2021.05.039","article-title":"Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.014_bib24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jtho.2023.10.014","article-title":"A phase 1b study of ivonescimab, a programmed cell death protein-1 and vascular endothelial growth factor bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy-naive NSCLC","volume":"19","author":"Wang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaci.2024.07.014_bib25","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaci.2024.07.014_bib26","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/19420862.2019.1624463","article-title":"Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease","volume":"11","author":"Benschop","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.jaci.2024.07.014_bib27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/cea.13706","article-title":"Circulating Ara h 6 as a marker of peanut protein absorption in tolerant and allergic humans following ingestion of peanut-containing foods","volume":"50","author":"Bernard","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.07.014_bib28","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1111\/all.14109","article-title":"The quest for ingested peanut protein in human serum","volume":"75","author":"Pahlow Mose","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.07.014_bib29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jaci.2023.08.035","article-title":"Widespread monoclonal IgE antibody convergence to an immunodominant, proanaphylactic Ara h 2 epitope in peanut allergy.","volume":"153","author":"Croote","year":"2024","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924007437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924007437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:16:39Z","timestamp":1730808999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924007437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0091674924007437"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.07.014","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical efficacy of peanut-specific IgG4 antibody therapeutic IGNX001","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}